Tymlos (abaloparatide; Radius Health/Teijin) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development. Despite binding to the same receptor (PTHR1), PTHrP and PTH have different functions in vivo. Although they both act to increase bone mineral density, PTHrP does not induce the subsequent unwanted bone resorption or hypercalcemic responses to the same extent as is seen with PTH. Compared with PTH, Tymlos has been shown to bind with a greater affinity to the conformation of PTHR that positively impacts bone formation.
LIST OF FIGURES
9 Figure 1: Tymlos for osteoporosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tymlos for osteoporosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tymlos for osteoporosis
LIST OF TABLES
6 Table 1: Tymlos drug profile
7 Table 2: Tymlos Phase III trial data in osteoporosis
8 Table 3: Tymlos planned Phase III trials in osteoporosis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.